Cardosal 20

Quick links to important sections

Cardosal 20

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Cardosal 20

Understanding Cardosal 20

Cardosal 20 is a prescription medication utilized primarily in the management of high blood pressure, also known as hypertension. It contains the active ingredient olmesartan medoxomil, which belongs to a class of drugs called angiotensin II receptor blockers (ARBs).

Mechanism of Action

The medication works by interacting with the hormonal system that regulates blood pressure. Specifically, it blocks the action of angiotensin II, a naturally occurring substance in the body that causes blood vessels to tighten and narrow. By preventing this action, Cardosal 20 allows the blood vessels to relax and widen, which facilitates smoother blood flow and helps the heart pump blood more efficiently throughout the body.

Therapeutic Purpose

The primary goal of using Cardosal 20 is to lower elevated blood pressure levels. Maintaining blood pressure within a target range is a critical component of cardiovascular health management. While the medication addresses the physiological aspects of hypertension, it is often used as part of a broader health strategy that may include dietary changes and other lifestyle modifications to support long-term vascular health.

Regulatory References

  1. Olmesartan - StatPearls
  2. EMA Public Assessment Report Olmesartan Medoxomil

What side effects are possible with Cardosal 20?

Possible side effects and safety information

The safety profile of Cardosal 20 (Olmesartan Medoxomil), an Angiotensin II Receptor Blocker (ARB), is based on official regulatory classifications that detail adverse reactions by frequency and affected body system.


Adverse Reaction Classification

Side effects are officially classified into frequency categories:

  • Common Reactions (may affect up to 1 in 10 people) typically involve systemic and neurological effects, such as dizziness, headache, and fatigue. Gastrointestinal issues like nausea and abdominal pain, and laboratory changes like increased blood urea or creatinine, are also listed as common.
  • Uncommon and Rare Reactions (affecting less than 1 in 100 people) encompass events like rash, hypotension (low blood pressure), and increases in liver enzymes.

Serious Safety Considerations

Official labeling highlights specific serious adverse reactions and population constraints.

Serious Adverse Reactions include the hypersensitivity event angioedema (swelling of the face, lips, or throat), which requires immediate attention. A rare but serious gastrointestinal disorder, sprue-like enteropathy, characterized by severe, chronic diarrhea, has been documented, sometimes with a delayed onset months to years after treatment initiation. Acute renal failure is also a documented rare risk.

Population-Specific Constraints establish that the use of Olmesartan Medoxomil is contraindicated during the second and third trimesters of pregnancy due to the risk of fetal harm. Furthermore, its use is not recommended in individuals with severe hepatic impairment (severe liver problems).

Overdose and Emergency Response

Official Overdose Manifestations

The official regulatory documentation identifies the primary clinical sign of overdosage as severe hypotension (low blood pressure), which is an exaggerated effect of the medication. This condition may manifest as dizziness, lightheadedness, or fainting (syncope). Changes in heart rate, including both tachycardia (fast heartbeats) and bradycardia (slow heartbeats), have also been documented in the context of overdose.

Potential Severe Outcomes and Management

Severe overdose carries a risk of significant systemic compromise, including progression to acute renal failure, oliguria (severely reduced urine output), and azotemia. Management is strictly symptomatic and supportive, as regulatory documents state that no specific antidote is known for this drug. Supportive measures for managing hypotension may involve placing the patient in the supine position and administering an intravenous infusion of normal saline.

When to Seek Immediate Help

Regulators mandate that individuals seek immediate medical attention for any known or suspected overdose of Cardosal 20. This action is required even if no symptoms are currently present. This guidance ensures timely intervention for potential severe outcomes. A specific regulatory note requires close observation for infants with a history of in utero exposure due to documented risks of fetal and neonatal injury.

Therapeutic Uses of Cardosal 20

What Cardosal 20 Treats: Main Uses and Benefits

Cardosal 20 (Olmesartan Medoxomil) is generally used for the long-term management of high blood pressure (hypertension) in patient groups where it is commonly used. Its core function is relevant for addressing symptoms related to systemic imbalance, specifically the persistent pathological pressure elevation within the arteries. Its use is considered relevant in contexts involving high blood pressure, and it may be used to support kidney health in people with diabetes.


Supporting Long-Term Stability

Cardosal 20 is commonly used to help with conditions characterized by periods of heightened physiological stress, such as sustained hypertension. This continuous management may assist with easing the strain placed on the heart and blood vessels, contributing to supporting healthy systemic vascular pressure. The goal is to help maintain a sense of stability when symptoms are not noticeable by supporting general well-being during symptomatic phases, contributing to easing the overall symptom load associated with chronic pressure elevation.

The medication is also considered relevant in clinical settings for patients with conditions presenting with systemic or localized discomfort related to renal function. This specialized use may assist with supporting the long-term functional stability of the kidneys in vulnerable patient groups like those with Type 2 Diabetes Mellitus.


Quick Fact: Relief for Systemic Strain
Main Therapeutic Area: Management of chronic high blood pressure
Key Benefit: Supports general well-being and functional stability

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Cardosal 20 (olmesartan medoxomil), an Angiotensin II Receptor Blocker (ARB), is primarily indicated for the treatment of high blood pressure (hypertension) in adults and pediatric patients six years of age and older. By lowering blood pressure, it helps reduce the risk of serious cardiovascular events like stroke and myocardial infarction (heart attack).


Who Should Not Use Cardosal 20? (Contraindications)

Consult your healthcare provider to determine if Cardosal 20 is safe for you. The medication is contraindicated and should not be used in the following situations:

  • Pregnancy: The drug can cause injury or death to the developing fetus, particularly during the second and third trimesters. It must be discontinued immediately if pregnancy is detected.
  • Allergy: Individuals with a known hypersensitivity or allergic reaction to olmesartan or any of its components.
  • Combination Therapy: Patients with diabetes mellitus who are concurrently taking a blood pressure medication containing aliskiren (a direct renin inhibitor). This combination is associated with an increased risk of hypotension, hyperkalemia, and renal complications.
  • Children: Use is generally not recommended in children under one year of age due to potential adverse effects on immature kidney development.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Cardosal 20 (olmesartan) can interact with several other medicinal products, requiring careful monitoring or specific adjustments to avoid adverse effects or reduced efficacy.


Clinically Significant Interactions

1. Dual Blockade of the Renin-Angiotensin System (RAS)

The combined use of olmesartan with other agents that block the RAS, such as ACE inhibitors, other Angiotensin II Receptor Blockers (ARBs), or aliskiren, increases the risk of hypotension, hyperkalemia, and changes in renal function. This dual blockade is generally avoided. Co-administration with aliskiren is contraindicated in patients with diabetes and avoided in patients with renal impairment (GFR less than 60 mL/min).

2. Non-Steroidal Anti-Inflammatory Agents (NSAIDs)

NSAIDs, including selective COX-2 inhibitors, may attenuate the antihypertensive effect of olmesartan. They can also lead to a deterioration of renal function, especially in elderly, volume-depleted, or those with pre-existing renal compromise. Renal function should be monitored upon initiation.

3. Agents Increasing Serum Potassium

Co-administration with potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium, or heparin can increase the risk of hyperkalemia. Serum potassium levels should be monitored.

4. Lithium

Concurrent use may lead to increased serum lithium concentrations and lithium toxicity. Monitoring of serum lithium levels is essential.

5. Colesevelam Hydrochloride

The bile acid sequestering agent, colesevelam, reduces the systemic exposure and peak concentration of olmesartan. To mitigate this interaction, it is advised to administer olmesartan at least 4 hours prior to the colesevelam dose.

Mechanism of Action

Core Mechanism: Inhibiting the Na^+/ K^+-ATPase Pump

Cardosal 20's primary molecular action is the selective inhibition of the Na^+/ K^+-ATPase enzyme, a cation pump situated on the cardiac cell membrane. This interaction initiates an ionic cascade by causing a modest rise in intracellular sodium ( [Na^+] i).


Modulating Intracellular Cation and Contractility Dynamics

The increased [Na^+] i reduces the chemical gradient required for the Na^+/ Ca^2+ exchanger (NCX) to efficiently expel calcium ( Ca^2+). This diminished NCX activity results in an elevated intracellular Ca^2+ concentration ( [Ca^2+] i) that increases the force of contraction (positive inotropy). The mechanism also engages the vagus nerve system, contributing to a decreased heart rate (negative chronotropy).


Suppression of the PI3K/Akt/mTOR Signaling Cascade

Beyond ion pump effects, Cardosal 20 acts as a down-regulator within the PI3K/Akt/mTOR pathway, a key molecular system associated with cell survival, growth, and proliferation. This activity influences pathways linked to hypertrophy and fibrosis, which is consistent with the modulation of cellular growth and structural changes in heart tissue.

Dosage and Administration Information

Cardosal 20 is administered orally and is available as a film-coated tablet in various strengths. The medication is prescribed to be taken once daily, and it may be ingested with or without food. To maintain consistent systemic exposure, it is generally recommended that the medicine be taken at approximately the same time each day.

For most adult patients, the standard starting dosage is 20 mg once daily, with the typical maintenance range extending up to a maximum dose of 40 mg per day. The dosing regimen involves a structured assessment period: the decision to increase or adjust the dose is generally considered after at least two weeks of continuous therapy, as the maximal blood pressure-lowering effect may take up to eight weeks to fully manifest.

Dosing guidance also addresses specific usage constraints. For individuals diagnosed with moderate renal impairment or moderate hepatic impairment, the maximum daily dose is often restricted to 20 mg once daily. In pediatric use (ages 6 to 16), administration is guided by specific weight-based dose recommendations. For patients unable to swallow the solid tablet form, an extemporaneous oral suspension can be prepared according to documented administration instructions.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Cardosal 20

This overview describes the types of research and clinical trials that have been conducted to evaluate Cardosal 20 (Olmesartan Medoxomil). It provides a look at what the research has explored and what is still uncertain, without offering any individual medical advice or making claims about specific future results.


Evidence for use in Managing High Blood Pressure (Hypertension)

Cardosal 20 was studied for individuals with high blood pressure in various research settings. The research for this indication includes Randomized Controlled Trials (RCTs). These short-term studies, often lasting 6 to 12 weeks, were designed to compare the effects of the medication against an inactive pill (placebo) or against other approved blood pressure medications. The studies focused on measurements of Systolic and Diastolic Blood Pressure (SBP and DBP) from the start of the trial.

Trials examined blood pressure measurements when compared against placebo or other agents in adults. Research also explored effects in pediatric patients across the 6 to 16 age range. The majority of documentation supporting this use focuses on blood pressure measurement itself, which is a surrogate outcome rather than the direct assessment of long-term health events like heart attacks or strokes.


Evidence for use in Supporting Kidney Health in People with Type 2 Diabetes

Cardosal 20 was evaluated in research programs that explored its effect in individuals with Type 2 Diabetes. These trials focused on outcomes related to systemic or functional imbalance associated with Type 2 Diabetes-related kidney conditions. The research utilized multi-year follow-up periods to examine measurements related to the onset of microalbuminuria (an early sign of kidney changes) and tracked composite renal endpoints.

For patients with advanced kidney changes, the documentation of combined renal outcomes demonstrated mixed findings across different studies. Regulatory documentation noted unexpected findings regarding cardiovascular outcomes in some high-dose groups during specific trials for this indication, which introduces uncertainty into the overall assessment for this population. Long-term effects for this group are not fully established.


What Research Indicates Remains Uncertain

A primary limitation across all indications is the focus on surrogate endpoints (such as blood pressure numbers and microalbuminuria) rather than long-term assessment of cardiovascular events. There is limited information available for outcomes spanning a decade or more.

Frequently Asked Questions (FAQ)

Common questions about Cardosal 20 (FAQ)


Q: Does Cardosal 20 have a generic version available?

Yes, Cardosal 20 contains the active ingredient olmesartan medoxomil, which is available as a generic medication. The FDA's official listing confirms that various generic versions of the 20 mg strength have been determined to be therapeutically equivalent to the original brand-name product.

Q: Is Cardosal 20 the same as other 'Cardosal' medicines?

Cardosal 20 contains 20 mg of the active ingredient, Olmesartan Medoxomil. Official product information indicates this medicine is also available in different strengths, such as 5 mg and 40 mg, and may be combined with other drugs in combination tablets.

Q: How quickly does Cardosal 20 start to work after I begin taking it?

The initial blood pressure-lowering effect may occur relatively quickly after starting the medicine. However, official documents indicate that the full, maximum benefit in lowering blood pressure may take up to two weeks of continuous therapy to become fully established.

Q: What are the most common side effects people report with Cardosal 20?

Studies indicate that the most common side effects, occurring in 1% to 10% of people, include dizziness, headache, and fatigue. Other common reactions include gastrointestinal issues like nausea, diarrhea, and abdominal pain, and certain laboratory changes.

Q: Is it normal to feel a little dizzy when first starting Cardosal 20?

Yes, dizziness is listed as one of the most common adverse reactions reported in clinical trials. As the body adjusts to the changes in blood pressure, this feeling may be more noticeable. Official information states this reaction may affect up to 1 in 10 people.

Q: If I miss a dose of Cardosal 20, what should I do?

Official guidance describes that if a dose is missed, it can be taken as soon as it is remembered. If it is almost time for your next scheduled dose, the guidance is to skip the missed dose entirely and only take the next dose at the regular time. The guidance states that double or extra doses should not be taken.

Q: Can Cardosal 20 cause weight gain or loss?

General weight change is not listed as a common side effect in official documents. However, a rare but serious adverse event called sprue-like enteropathy is noted in post-marketing reports, and one of its characteristics is severe, chronic diarrhea with substantial weight loss.

Q: What happens if I stop taking Cardosal 20 suddenly?

Regulatory studies of abrupt withdrawal following treatment have not indicated a risk of rebound hypertension (a sudden, sharp increase in blood pressure). The decision to stop the medication is a matter for consultation with a healthcare professional.

Q: How long does Cardosal 20 stay in your system?

The active substance, Olmesartan, has an elimination half-life of approximately 13 hours in the blood. Studies show that consistent levels of the drug in the body are typically achieved within 3 to 5 days of starting a once-daily regimen.

Q: Is Cardosal 20 a controlled substance?

Cardosal 20, which is Olmesartan Medoxomil, is not classified as a controlled medication by the DEA schedule. It is not associated with dependency.

Q: Are there any long-term side effects associated with Cardosal 20 use?

While long-term safety data spanning a decade or more are limited, one rare and serious delayed-onset event is reported: sprue-like enteropathy. This condition, characterized by severe chronic diarrhea and weight loss, has been documented to sometimes occur months to years after starting treatment.

Q: Can Cardosal 20 affect sleep or cause insomnia?

Official adverse reaction lists do not consistently list insomnia or specific sleep disorders as a common side effect. Reported reactions involving the nervous system include dizziness and headache.

Q: Does Cardosal 20 make you tired?

Fatigue (tiredness) is officially listed among the common adverse reactions reported in clinical trials, meaning it may affect up to 1 in 10 people taking the medication.

Q: Can Cardosal 20 interact with alcohol?

Official information indicates that alcohol consumption can increase the risk of orthostatic hypotension, which is a sudden drop in blood pressure when moving from sitting or lying down to a standing position. Patients who consume alcohol are advised to consult with their doctor about this interaction.

Q: What should I do if I think I have accidentally taken too much Cardosal 20?

The primary clinical finding expected from an accidental overdose of this medication is severe hypotension (low blood pressure). Official guidance states that a Poison Control center or emergency medical help should be contacted.

Q: Can Cardosal 20 be taken with common dietary supplements like vitamins?

Regulatory documents include a warning that taking this medicine with over-the-counter potassium supplements or salt substitutes containing potassium can increase the risk of high blood potassium (hyperkalemia). The labeling does not consistently note major interactions with common standard vitamins.

Q: Is Cardosal 20 addictive?

No, Cardosal 20 (Olmesartan Medoxomil) is not classified as a controlled substance, nor is it associated with dependency. Regulatory studies of abrupt withdrawal did not suggest dependency or rebound effects.

Q: Can children or teenagers be prescribed Cardosal 20?

Yes, Cardosal 20 is officially indicated for the treatment of high blood pressure in pediatric patients who are six years of age and older. Use is not generally recommended in children under one year of age.

Q: How often are follow-up appointments needed when taking Cardosal 20?

The dosing is individualized, and official guidelines suggest that the decision to adjust the dose is typically made after at least two weeks of continuous therapy. Close medical supervision, including monitoring of kidney function and potassium levels, is recommended when starting.

Q: Can Cardosal 20 affect your mood or mental health?

Official adverse reaction lists do not consistently list common psychiatric or mood disorders. However, central nervous system effects such as dizziness and headache are reported as common side effects.

Q: Is Cardosal 20 a relatively new medication?

The original FDA approval date for the brand-name formulation of Olmesartan Medoxomil was April 5, 2002. This indicates it has been in use for over two decades.

Q: Are there different brands of Cardosal 20 that are interchangeable?

The FDA Orange Book indicates that various generic versions of Olmesartan Medoxomil in the 20 mg strength have been determined to be therapeutically equivalent to the original brand-name product, meaning they are considered interchangeable.

Q: Do all patients experience benefits from Cardosal 20?

Clinical trials showed that blood pressure reduction was achieved across various patient subgroups. However, official information notes that a subset of patients required dose increases or the addition of other medicines to achieve control, and that the blood pressure-lowering effect was noted to be smaller in black patients.

Q: Is Cardosal 20 known to cause problems with sexual function?

Sexual dysfunction is not commonly listed as an adverse reaction in the official product labeling. Other adverse events involving the urogenital system have been reported in post-marketing experience.

Q: Does Cardosal 20 contain any gluten or common allergens?

The inactive ingredients in the tablet formulation often include common components like lactose monohydrate and starch. While the drug itself is generally free of gluten, patients with specific sensitivities should review the full inactive ingredient list with their pharmacist.

Q: Does Cardosal 20 interact with grapefruit?

While the single-ingredient product labeling may not contain this specific warning, other similar combination products containing the active ingredient olmesartan may caution against grapefruit consumption, particularly due to potential interactions with other combined drugs.

Q: Can women who are planning to become pregnant use Cardosal 20?

Official documents state that drugs in this class can cause injury and death to a developing fetus. If pregnancy is detected, the medicine must be stopped as soon as possible. For patients planning a pregnancy, official information advises a discussion with a healthcare provider regarding alternative options.

Q: Is Cardosal 20 known to cause any skin rashes or allergic reactions?

Less common skin reactions like rash and hives have been reported. A more serious hypersensitivity event called angioedema (swelling of the face, lips, or throat) has been documented in post-marketing experience, requiring immediate attention.

Q: Does Cardosal 20 cause constipation or diarrhea?

Official reports indicate that diarrhea is listed among the common adverse reactions. A severe, chronic diarrhea accompanied by substantial weight loss may indicate the rare but serious adverse event known as sprue-like enteropathy.

How should Cardosal 20 be stored and disposed of?

How to Store and Dispose of Cardosal 20?

Cardosal 20 (Olmesartan Medoxomil) tablets require strict adherence to regulatory storage conditions to maintain product integrity.


Official Storage Requirements

Temperature and Protection: The tablets must be stored at Controlled Room Temperature (CRT), ideally between 20 C to 25 C (68 F to 77 F). Storage must be away from heat and direct light, and the product must be protected from moisture and kept from freezing.

Container and Safety: The medication must be kept in a closed, tightly closed container and stored out of the reach of children. Blister packs have an additional rule requiring storage below 30 C.


Disposal Protocol

Unused or expired Cardosal 20 should be discarded by following the official instruction to ask a healthcare professional how to dispose of the product. Disposal must be in accordance with local, regional, and national regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Cardosal 20 found in:

A-Z Index: